Zentalis Pharmaceuticals, Inc.
ZNTL
$1.34
-$0.03-2.19%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 47.81% | -31.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.36% | -7.72% | |||
| Operating Income | 3.36% | 7.72% | |||
| Income Before Tax | 0.68% | 44.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.68% | 44.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.68% | 44.34% | |||
| EBIT | 3.36% | 7.72% | |||
| EBITDA | 3.37% | 7.50% | |||
| EPS Basic | 0.88% | 44.58% | |||
| Normalized Basic EPS | -3.54% | 32.29% | |||
| EPS Diluted | 0.88% | 44.58% | |||
| Normalized Diluted EPS | -3.54% | 32.29% | |||
| Average Basic Shares Outstanding | 0.20% | 0.44% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||